NeoGenomics (Nasdaq:NEO) - Cotización, noticias y análisis

Resumen de acción NEO

NeoGenomics, Inc. explota una red de laboratorios de análisis centrados en el cáncer en Estados Unidos y el Reino Unido.

Acerca de la empresa

NEO análisis fundamental
Puntuación del copo de nieve
Valoración	2/6
Crecimiento futuro	1/6
Resultados anteriores	0/6
Salud financiera	4/6
Dividendos	0/6

Recompensas

Cotiza un 73.4% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los ingresos de 9.73%

Análisis de riesgos

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de NeoGenomics, Inc.

Addus HomeCare

NasdaqGS:ADUS

US$2.2b

AMN Healthcare Services

NYSE:AMN

US$2.4b

BrightSpring Health Services

NasdaqGS:BTSG

US$2.2b

Agiliti

NYSE:AGTI

US$1.4b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de NeoGenomics
Precios históricos de las acciones
Precio actual de la acción	US$17.27
Máximo en 52 semanas	US$21.22
Mínimo de 52 semanas	US$11.03
Beta	1.18
11 mes Cambio	23.98%
Variación en 3 meses	17.32%
Cambio de 1 año	6.31%
3Variación en 3 años	-63.63%
Variación en 5 años	-33.58%
Variación desde la OPV	564.23%

Noticias y actualizaciones recientes

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Jul 15

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Apr 22

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

Apr 08

Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Feb 11

Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

Jan 07

NeoGenomics: Gambling On Growth

Dec 16

NeoGenomics: Profitability Headwinds Compress Valuation, Shares

Sep 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Sep 24

Rentabilidad de los accionistas

	NEO	US Healthcare	Mercado US
7D	13.8%	5.2%	-2.3%
1Y	6.3%	9.6%	16.9%

Rentabilidad vs. Industria: Los resultados de NEO fueron inferiores a los de la industria US Healthcare, que obtuvo un rendimiento del 3.5% el año pasado.

Rentabilidad vs. Mercado: NEO obtuvo unos resultados inferiores a los del mercado US, que fueron del 22.3% el año pasado.

Volatilidad de los precios

Is NEO's price volatile compared to industry and market?
NEO volatility
NEO Average Weekly Movement	7.5%
Healthcare Industry Average Movement	7.2%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: NEO no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de NEO (6%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2001	2,100	Chris Smith	www.neogenomics.com

NeoGenomics, Inc. explota una red de laboratorios de análisis centrados en el cáncer en Estados Unidos y el Reino Unido. Opera a través de los segmentos de Servicios Clínicos y Diagnóstico Avanzado. La empresa ofrece servicios de pruebas a hospitales, centros académicos, patólogos, oncólogos, médicos, empresas farmacéuticas y laboratorios clínicos.

Resumen de fundamentos de NeoGenomics, Inc.

¿Cómo se comparan los beneficios e ingresos de NeoGenomics con su capitalización de mercado?
Estadísticas fundamentales de NEO
Capitalización bursátil	US$2.21b
Beneficios(TTM)	-US$78.54m
Ingresos (TTM)	US$628.25m

3.5x

Ratio precio-ventas (PS)

-28.2x

Ratio precio-beneficio (PE)

¿Está NEO sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NEO
Ingresos	US$628.25m
Coste de los ingresos	US$360.39m
Beneficio bruto	US$267.86m
Otros gastos	US$346.41m
Beneficios	-US$78.54m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.61
Margen bruto	42.64%
Margen de beneficio neto	-12.50%
Ratio deuda/patrimonio	58.9%

¿Cómo se ha desempeñado NEO a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción NEO

Recompensas

Análisis de riesgos

Competidores de NeoGenomics, Inc.

NasdaqGS:ADUS

US$2.2b

NYSE:AMN

US$2.4b

NasdaqGS:BTSG

US$2.2b

NYSE:AGTI

US$1.4b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

NeoGenomics, Inc. Revises Earnings Guidance for the Full-Year 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q2, 2024 Results on Jul 29, 2024

NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024

Recent updates

NeoGenomics, Inc. Revises Earnings Guidance for the Full-Year 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q2, 2024 Results on Jul 29, 2024

NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Price target increased by 7.2% to US$21.55

Full year 2023 earnings: EPS exceeds analyst expectations

NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024

NeoGenomics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

NeoGenomics Laboratories, Inc. to Appeal Ruling

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Consensus estimates of losses per share improve by 11%

NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neogenomics, Inc. Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

NeoGenomics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

NeoGenomics, Inc.'s RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

NeoGenomics, Inc. and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

NeoGenomics, Inc. to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

Price target increased by 7.7% to US$21.64

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.40 loss in 1Q 2022)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics, Inc. Announces Results of a New Study of the RaDaR Assay in Patients with Muscle-Invasive Bladder Cancer

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

The Klein Law Firm Announces Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Neogenomics, Inc. Shareholders

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Gibbs Law Group Announces Files Class Action Lawsuit Against NeoGenomics Inc

NeoGenomics, Inc. Announces Executive Changes

Neogenomics, Inc. Announces Radar Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics Appoints David Perez to its Board of Directors

NeoGenomics, Inc. Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

NeoGenomics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NeoGenomics: Market Punishment Continues, But Looks Justified

NeoGenomics grants CEO restricted shares, stock options

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

NeoGenomics rises ~14% on strong Q2 result

NeoGenomics, Inc. Appoints Chris Smith as Chief Executive Officer, Effective August 15, 2022

NeoGenomics gets new CEO

Price target decreased to US$17.75

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

NeoGenomics, Inc.(NasdaqCM:NEO) dropped from Russell 2000 Growth-Defensive Index

NeoGenomics, Inc. Announces Resignation of Douglas Brown as Chief Strategy and Corporate Development Officer